Perrigo Company Public Limited Company
Perrigo Company plc (PRGO) is a global consumer healthcare manufacturer best known for over‑the‑counter medicines, infant formulas and private‑label personal care products sold through supermarkets, pharmacies and online retailers. With a market capitalisation around $3.02 billion, Perrigo blends manufacturing scale with long‑term retailer relationships and a focus on branded and store‑brand consumer goods. Investors should note the company’s exposure to retail channels, commodity and input‑costs, and regulatory oversight that can affect margins and product launches. Perrigo has pursued portfolio reshaping and cost measures in recent years to stabilise margins, but sales and profits can fluctuate with pricing pressure, competition and supply‑chain disruption. This summary is for educational purposes only and not personalised investment advice; past performance is not a reliable indicator of future returns and suitability depends on your circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Perrigo's stock with a target price of $19.33, indicating growth potential.
Financial Health
Perrigo shows solid revenue and cash flow generation, but faces challenges with profitability margins.
Dividend
Perrigo's high dividend yield of 9.83% offers a substantial return for income-seeking investors. If you invested $1000 you would be paid $98.30 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRGO
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: September 2, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Private‑label strength
Perrigo’s long relationships with retailers support steady sales in store‑brand products, though pricing pressure can squeeze margins.
Global distribution reach
A broad footprint gives scale and channel diversity, but exposes the company to currency, regulatory and regional demand risks.
Margins and costs
Operating profits are sensitive to input and freight costs; cost control helps, yet performance can vary with macro and supply‑chain shifts.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
